bremelanotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
== Biological activity == Protolichesterinic acid exhibits diverse biological activities, including antimicrobial, enzyme inhibitory, and anticancer properties. Studies with the compound isolated from Usnea albopunctata have demonstrated broad-spectrum antimicrobial activity. It shows strong antibacterial effects against Klebsiella pneumoniae (minimum inhibitory concentration 0.25 μg/mL) and Vibrio cholerae (0.5 μg/mL), exceeding the potency of ciprofloxacin. The compound is also active against methicillin-resistant Staphylococcus aureus (MRSA) and shows notable antifungal activity against Trichophyton rubrum, surpassing amphotericin B in potency. As an inhibitor, protolichesterinic acid selectively targets 5-lipoxygenase while showing minimal effect on cyclooxygenase. This selective inhibition suggests potential applications in treating inflammatory conditions, particularly those involving leukotriene bronchoconstrictors. Structure-activity studies indicate that while the stereospecific side chain and exocyclic double bond are not essential for activity, the carboxylic acid group plays a crucial role. The compound also inhibits the DNA polymerase activity of human immunodeficiency virus-1 reverse transcriptase (HIV-1 RT). Research has revealed that protolichesterinic acid affects cancer cell metabolism by disrupting mitochondrial function through inhibition of oxidative phosphorylation and enhancement of glycolysis. The compound undergoes cellular processing via the mercapturic pathway, forming conjugates with glutathione.
=== Cuban Thaw and attempts to repair relationship === In 2011, Lazaro Cuesta Valdes was elected as the Grand Commander of the Supreme Council of Cuba. After his election, the Supreme Council created a Facebook page, launched an updated webpage, and launched the first International Conference on Freemasonry and Integration to Current Society. Between 2012 and 2014, Grand Commander Cuesta Valdes travelled around the world, first to Rome, and then to visit the Supreme Councils of the United States' Southern Jurisdiction and Northern Jurisdiction, in Ohio and Washington, D.C. Informally, he also met with leaders of the Cuban exile Freemasonry community in Miami to strengthen relations with the United States. In October 2013, the Supreme Council of Cuba held an open meeting and invited Cuban Masons living anywhere to Havana to discuss the fractured state of Cuban Freemasonry. Grand Master Gutierrez Torres attended and drafted Official Message No. 6 after discussions with members of the diaspora. In April 2014, while still in prison, Alan Gross launched a hunger strike to protest his treatment by both Cuba and the United States. When the Associated Press leaked the ZunZuneo program documents to the public, Senator Patrick Leahy called it: "Dumb, dumb, dumb." Leahy then led the Senate committee review of the debacle. On December 17, 2014, Alan Gross was released from Cuban prison in exchange for three members of the Cuban Five, who had been detained in the United States and charged with espionage. On December 10, 2016, the Lazaro F.
In France, students attending clinical practice are known as "externes" and newly qualified practitioners training in hospitals are known as "internes". The residency, called "Internat", lasts from three to six years (depending on the speciality) and follows a competitive national ranking examination. It is customary to delay submission of a thesis. As in most other European countries, many years of practice at a junior level may follow. French residents are often called "doctor" during their residency. Literally speaking, they are still students and become M.D. only at the end of their residency and after submitting and defending a thesis before a jury.
== Properties == N-Hydroxyphthalimide exists in two polymorphs, colorless and yellow, In the colorless white form, the NOH group is rotated about 1.19° from the plane of the molecule, while in the yellow form it is much closer to planarity (0.06° rotation). The color of the synthesized N-hydroxyphthalimide is determined by the solvent used; the color transition from white to yellow is irreversible. N-Hydroxyphthalimide forms strongly colored, mostly yellow or red salts with alkali and heavy metals, ammonia and amines. Hydrolysis of N-hydroxyphthalimide by the addition of strong bases produces phthalic acid monohydroxamic acid by adding water across one of the carbon–nitrogen bonds. N-Hydroxyphthalimide ethers, on the other hand, are colorless and provide O-alkylhydroxylamines by alkaline hydrolysis or cleavage through hydrazine hydrate. The "phthalylhydroxylamine" reported by Cohn was known to have a molecular formula of C8H5NO3, but the exact structure was not known. Three possibilities were discussed and are shown in the Figure below: a mono-oxime of phthalic anhydride ("phthaloxime", I), an expanded ring with two heteroatoms, (2,3-benzoxazine-1,4-dione, II), and N-hydroxyphthalimide (III). It was not until the 1950s that Cohn's product was definitely shown to be N-hydroxyphthalimide (III).
Sources: en.wikipedia.org
Proposals are published to give Members of the Senedd a 6% pay rise, taking the wages for a backbench MS to £76,380 in 2025–26, up from £72,057. 9 January – Former Prime Minister Liz Truss sends Keir Starmer a legal "cease and desist" letter demanding that he stop saying she "crashed the economy". Mick Lynch announces his retirement as general secretary of the National Union of Rail, Maritime and Transport Workers. 10 January – Local councils have until this date to decide whether to delay their participation in the May local elections. Ten Reform UK councillors in Derbyshire resign from the party in protest at Nigel Farage's leadership, saying that the party is being run in an "increasingly autocratic manner" and "has lost its sense of direction" since Farage took over as leader. In response, Farage says the members were put forward by a "rogue branch" of the party and that "none of them passed vetting". 13 January – Buckingham Palace confirms that King Charles III will travel to Auschwitz concentration camp to attend an event marking the 80th anniversary of its liberation on 27 January. Michael Ellam is appointed at the Cabinet Office's second permanent secretary, European Union and International Economic Affairs. As Chancellor Rachel Reeves faces mounting criticism over her handling of the economy against a backdrop of a falling pound and increases in government borrowing, Downing Street says she will remain in her role "for the whole of this Parliament".
People with cirrhosis have a 40% lifetime risk of developing hepatic encephalopathy. The median survival after the development of hepatic encephalopathy is 0.9 years. Mild hepatic encephalopathy (also known as covert hepatic encephalopathy), in which symptoms are more subtle, such as impairments in executive function, poor sleep or balance impairment is also associated with a higher risk of hospitalization and death (18% in those with covert hepatic encephalopathy vs 3% in those with cirrhosis and no HE).
=== Tuberoinfundibular dopaminergic neurons === The cell bodies of TIDA neurons are located in the arcuate nucleus (infundibular nucleus) of the mediobasal hypothalamus. Their axons project to the external zone of the median eminence, where dopamine is released into the fenestrated capillaries of the primary portal plexus. First identified by Kjell Fuxe in 1963–1964, TIDA neurons are distinguished from nigrostriatal and mesolimbic dopamine populations by their neuroendocrine function. TIDA neurons display intrinsic oscillatory activity and are regulated by gonadal steroids and by prolactin itself.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.